Status:
COMPLETED
Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Atrial Fibrillation
Atrial Flutter
Eligibility:
All Genders
Phase:
PHASE3
Brief Summary
The trial seeks to determine if apixaban, an investigational anticoagulant (blood-thinner) is as effective as standard therapy (warfarin) in preventing stroke and systemic embolism in subjects with at...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Males and females ≥ 18 yrs with atrial fibrillation (AF) and one or more of the following risk factors for stroke:
- Age ≥ 75, previous stroke
- transient ischemic attack (TIA) or Systemic Embolism (SE)
- Symptomatic congestive heart failure or left ventricular dysfunction with left ventricular ejection fraction (LVEF) ≤ 40%
- Diabetes mellitus or hypertension requiring pharmacological treatment
Exclusion
Key Trial Info
Start Date :
December 31 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 25 2011
Estimated Enrollment :
20976 Patients enrolled
Trial Details
Trial ID
NCT00412984
Start Date
December 31 2006
End Date
May 25 2011
Last Update
July 3 2018
Active Locations (1111)
Enter a location and click search to find clinical trials sorted by distance.
1
Cardiovascular Associates, Pc
Birmingham, Alabama, United States, 35209
2
Alabama Internal Medicine Pc
Birmingham, Alabama, United States, 35235
3
Birmingham Heart Clinic P.C.
Birmingham, Alabama, United States, 35235
4
Heart Center, Inc.
Huntsville, Alabama, United States, 35801